In Brief: St. Jude/Cyberonics
This article was originally published in The Gray Sheet
Executive Summary
St. Jude/Cyberonics: Merger agreement cleared by Cyberonics shareholders, the firm announces July 23. The action gives St. Jude until October 18 to exercise its option to complete a $72 mil. merger transaction under an April 8 agreement -- time to evaluate results from a second clinical trial of Cyberonics' NCP (NeuroCybernetic Prosthesis) neurological stimulation device ("The Gray Sheet" April 15, I&W-3). Cyberonics also completes the sale of 2.2 mil. new shares of common stock to St. Jude at $5.50 each for an aggregate of $12 mil. -- the merger agreement called for the equity financing upon Cyberonics shareholder approval...
You may also be interested in...
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.